Global approved new drugs in 2020: retrospect and prospect
Mengshang Wu, Yangyang Sun, Q. Chen, Zhenzhen Yang, X. N. Zheng · Zhongguo xin yao zazhi · 2021
The COVID-19 epidemic has swept the world in 2020, posing a major threat to human life and health. The global biopharmaceutical landscape will also change. The Center for Drug Evaluation and Research (CDER) of the US FDA approved 53 innovative drugs in 2020, 40 of which were first approved worldwide. The European EMA approved 34 innovative medicines throughout the year, including 6 for the first approval in the world. Japan's Medical Products and Medical Devices Agency (PMDA) approved 38 innovative drugs throughout the year, including 13 for the first approval in the world. National Medical Products Administration (NMPA) approved 48 innovative drugs throughout the year, 9 of which were developed by local companies and approved for the first time in the world. The launch of these new drugs will provide brand new therapies or more treatment options for a variety of diseases. This paper reviewed the new drugs approved for the market in the US, EU, Japan and China in 2020, and gave a brief outlook on the new drug development in 2021, aiming to provide reference for people engaged in new drug research and development.